

1 **Foot and Mouth Disease Vaccine Distribution Exercise and Proof of Concept for**
2 **Partnership with an Independent Vaccine Distribution Company**

3

4 **Kristen K. Clark, DVM, MPH, DACVPM¹; Jeffrey Kaisand, DVM²; Amanda Chipman,**
5 **BS²; Jane Galyon, MS¹; James A. Roth, DVM, PhD, DACVM^{1*}**

6 **¹Center for Food Security and Public Health (CFSPH), College of Veterinary Medicine,**
7 **Iowa State University, Ames, IA 50011**

8 **² Iowa Department of Agriculture and Land Stewardship, Des Moines, IA.**

9

10 ***Corresponding author: Dr. Roth (jaroath@iastate.edu)**

11

12 **Abstract**

13 To better prepare for a potential foot and mouth disease (FMD) outbreak, the U.S. Department of
14 Agriculture (USDA) and the Iowa Department of Agriculture and Land Stewardship (IDALS)
15 conducted a two-part exercise. Phase 1 was designed to validate end-to-end vaccine logistics
16 processes from FMD confirmation in livestock in Iowa through vaccine receipt from the
17 overseas manufacturer. Phase 2 was a proof of concept, in which IDALS partnered with an
18 independent vaccine distributor to manage the placebo FMD vaccine cold storage, repacking,
19 and distribution process. Independent distributors are already equipped to package, ship, and
20 track the mass distribution of animal health supplies while maintaining the cold chain and chain
21 of custody. In an FMD outbreak, this approach would increase efficiency of the response and
22 reduce time lost by securing cold storage, breaking down pallets, re-packaging vaccine vials, and
23 tracking shipments by federal or state officials who have insufficient personnel and limited or no
24 relevant experience. This would also allow federal and state officials to concentrate their efforts
25 on other vital response activities. Based on the outcomes of this exercise, the authors recommend
26 that the USDA consider an alternative approach to distribution of FMD vaccine during an
27 outbreak. Instead of distributing directly to states, IDALS encourages USDA to consider using
28 one or more independent vaccine distributors and coordinating with the distributor(s) ahead of an
29 outbreak.

30

31 **Introduction**

32 Foot and mouth disease (FMD) is a highly contagious viral disease that primarily affects cloven-
33 hooved (two-toed) animals. It is considered one of the most important transboundary animal
34 diseases in the world. Almost 3 billion doses of vaccine are produced worldwide each year to

35 control the disease¹. There are seven major serotypes of FMD and more than 60 strains².

36 Immunity to one serotype does not cross-protect an animal from infection with other serotypes
37 and not all strains within a serotype cross-protect².

38

39 The introduction of foot and mouth disease virus (FMDV) into the United States would have
40 devastating impacts on the U.S. economy, including significant impacts from the immediate loss
41 of international trade. In 2021, the U.S. exported an estimated \$10.58 billion USD in beef
42 products³, \$7.71 billion USD in pork products⁴, and \$7.66 billion USD in dairy products⁵. Other
43 costs directly associated with a foreign animal disease (FAD) eradication effort include
44 depopulation, indemnity, disposal, and virus elimination. In addition, there are direct and indirect
45 costs related to lost production, unemployment, and losses in related businesses.

46

47 The State of Iowa would be severely impacted by an FMD outbreak as Iowa ranks first in the
48 nation in pork production, in the top 10 states for beef production, and in the top 15 states for
49 dairy production⁶. The very high number and density of FMD-susceptible animals in Iowa make
50 readiness for FMD vaccination a top priority. The importance of livestock to Iowa's state
51 economy creates a much higher risk of economic, social, financial, and environmental
52 consequences from an outbreak than almost any other state. It is important that Iowa livestock
53 sectors prepare multiple strategies for dealing with an FMD outbreak. This includes having the
54 ability to quickly identify and eradicate cases and, if necessary, control disease spread through
55 vaccination.

56

57 The April 20, 2021 draft of the Iowa Emergency Foot and Mouth Disease Vaccination Plan⁷
58 states that IDALS is responsible for securely storing vaccine and distributing the correct number
59 of FMD vaccine doses to Authorized and Accredited Veterinarians within the state. Authorized
60 and Accredited Veterinarians then have responsibility for obtaining vaccine from the state
61 distribution point, properly storing and accounting for all vaccine assigned to them, maintaining
62 adequate cold chain storage and chain of custody, overseeing administration of vaccine to
63 animals on designated premises, and ensuring that vaccinated animals are properly identified and
64 tracked. However, many states, including the State of Iowa, are under-resourced to
65 operationalize these efforts in the event of an FMD outbreak.

66

67 Partnering with an independent vaccine distributor(s) during an FMD outbreak would help to
68 ensure proper and efficient handling and tracking of this valuable resource and would allow State
69 officials to focus more of their efforts on other vital response activities. Distributors and
70 veterinary clinics handle vaccine in a safe and efficient manner on a daily basis.

71

72 To better prepare for vaccination in a potential FMD outbreak, IDALS participated in a U.S.
73 Department of Agriculture (USDA) Animal and Plant Health Inspection Service (APHIS)
74 exercise to validate end-to-end vaccine logistics processes from FMD confirmation in livestock
75 in Iowa through vaccine receipt from the overseas manufacturer. As a proof of concept, IDALS
76 then partnered with MWI Animal Health (MWI), a part of Amerisource Bergan and an
77 independent vaccine distributor, to manage the placebo FMD vaccine cold storage, repacking,
78 and distribution process. A summary of the exercise, proof of concept, and recommendations
79 based on exercise play and findings from the proof of concept are presented here.

80

81 **Disclaimer**

82 The events outlined herein describe a fictitious scenario developed for exercise purposes and do
83 not represent an actual outbreak or case of FMD diagnosed in the United States. All vaccine
84 shipped in this exercise was placebo vaccine.

85

86 **Overview of Exercise**

87

88 This exercise consisted of two phases. Phase One was organized by the USDA National
89 Veterinary Stockpile (NVS) and Phase Two was organized by IDALS. Phase One took place
90 from August 31 to September 9, 2021, with participants representing USDA-APHIS, the State of
91 Iowa, an overseas vaccine manufacturer, and MWI Animal Health. This phase of the exercise
92 was designed to validate the end-to-end FMDV vaccine logistics processes for the United States
93 from the point of hypothetical FMD confirmation through placebo vaccine delivery to affected
94 states. Phase Two of the exercise took place from September 8 to September 15, 2021, with
95 participants representing USDA-APHIS, the State of Iowa, State Animal Health Officials from
96 four additional states, MWI Animal Health, the Iowa State University Center for Food Security
97 and Public Health, and producers and practicing veterinarians in five states. This phase of the
98 exercise was designed to test distribution of FMD placebo vaccine through normal vaccine
99 distribution channels from an Iowa-designated independent vaccine distributor to veterinary
100 clinics or production companies in the following states: California, Iowa, Kansas, Minnesota,
101 and North Carolina.

102

103 **Phase One**

104 Phase One of the exercise began with hypothetical suspect FMD cases on hog farms in two Iowa
105 counties. Exercise play began on August 31, 2021, with sample collection by a Foreign Animal
106 Disease Diagnostician (FADD) and samples submitted to the USDA APHIS Foreign Animal
107 Disease Diagnostic Laboratory (FADDL) at Plum Island, New York. For exercise play, an
108 epidemiologic investigation was launched immediately, and a conference call was held with
109 appropriate personnel from USDA-APHIS and the State of Iowa to coordinate efforts and plan
110 the next steps. Exercise samples were designated as presumptive positive based on polymerase
111 chain reaction (PCR) testing and internal notifications were made within USDA-APHIS and the
112 State of Iowa. USDA APHIS's National Veterinary Stockpile (NVS) was notified of the
113 presumptive positive and instructed to prepare for activation of the North American Foot and
114 Mouth Disease Vaccine Bank (NAFMDVB).

115
116 Virus isolation and sequencing were assumed to be completed within 36 hours and confirmed
117 that the samples were positive for FMD. The USDA-APHIS Chief Veterinary Officer (CVO)
118 approved the use of placebo vaccine as part of the exercise response efforts and the NAFMDVB
119 was activated. In accordance with the State of Iowa's DRAFT Emergency Foot and Mouth
120 Disease Vaccination Plan⁷, IDALS submitted a request to USDA for 231,000 doses of vaccine
121 (two full pallets) and this request was approved by the CVO. The NAFMDVB vaccine
122 manufacturer immediately initiated converting the placebo vaccine antigen concentrate into a
123 finished placebo vaccine for exercise play. Arrangements were made for the placebo vaccine to
124 be exported to the United States.

125

126 Two pallets of placebo vaccine were shipped on September 6, arrived in the U.S. on September
127 7, and were cleared through customs. USDA-APHIS obtained custody of both pallets and
128 confirmed adequate cold chain conditions were maintained (2-8 °C) throughout the flight via
129 review of temperature logs. USDA-APHIS then transferred the placebo vaccine to the NVS third
130 party logistics company (3PL). On September 8, the 3PL delivered the placebo vaccine in a
131 refrigerated truck to the State of Iowa’s designated cold storage site, MWI Animal Health, an
132 independent vaccine distributor located in Edwardsville, Kansas (hereafter referred to as
133 “MWI”). IDALS staff were present to receive the vaccine. Upon arrival, the truck seal was
134 inspected and found to be intact. IDALS staff reviewed the temperature logs and verified that
135 both pallets maintained adequate cold chain conditions throughout transport. IDALS verified the
136 number of vaccine vials in the shipment and added instructional leaflets indicating that this was a
137 placebo vaccine and information from the USDA Center for Veterinary Biologics (CVB)
138 approved vaccine label to each box. Custody of the placebo vaccine was transferred from USDA
139 to IDALS. This completed Phase One of the exercise and initiated Phase Two.

140

141 **Phase Two**

142

143 As proof of concept of partnering with a vaccine distributor to handle, track and deliver vaccine
144 to veterinarians, IDALS partnered with MWI during Phase Two of this exercise. After IDALS
145 assumed custody of the placebo vaccine at the designated cold storage facility of MWI, custody
146 was transferred to MWI. The vaccine was securely stored in the MWI cold storage facility which
147 had a temperature-monitoring system connected to the facility’s security system. IDALS
148 provided MWI with a list of addresses and number of doses where the placebo vaccine was to be

149 shipped. MWI utilized routine packaging, shipping, and tracking procedures to distribute
150 specified amounts of the placebo vaccine (two boxes per site, each containing 10 cases of 10
151 vials per case; 100cc/50 doses per vial for a total of 10,000 doses per site) to the IDALS-
152 designated Authorized Veterinarians at 20 sites in five states on September 14 and 15, 2021.
153 Sites in five states were selected working with the appropriate State Animal Health Official in
154 each state to exercise the concept of a single distributor receiving intact pallets of vaccine and
155 distributing to authorized veterinarians in multiple states. MWI included a temperature indicator
156 in each box shipped to verify if temperature was maintained between 2-8 °C during transit. MWI
157 uses a robust inventory and tracking system for chain of custody, and once shipped, IDALS
158 received tracking numbers for each shipment. All cold chain and chain of custody procedures
159 comply with U.S. Food and Drug Administration’s Code of Federal Regulations and are
160 regularly audited and enforced. Upon receipt of the shipments, authorized personnel at
161 predetermined veterinary clinics and production companies verified the quantity of placebo
162 vaccine and maintenance of cold chain via the temperature indicator included in each box.
163 Authorized personnel reported this information, along with any issues noted, to IDALS using
164 documentation that IDALS provided prior to the exercise. Photos were also taken at each site to
165 document the receipt and condition of the vaccine and the temperature indicators (shown in
166 Figure 1). Issues noted included one leaking vaccine bottle, one temperature indicator out of
167 range, and inability to locate temperature indicators in one or both boxes at four different sites. In
168 a real-life event, Authorized Veterinarians would be responsible for overseeing the
169 administration of vaccine to animals on premises specified by their state animal health official
170 and ensuring that animals are properly identified and tracked. Once the placebo vaccine was
171 received and receipt and condition were documented, Phase Two of the exercise concluded. For

172 the purposes of this exercise, authorized personnel returned all placebo vaccine to the IDALS
173 office.

174

175 **Issues Identified**

176 For the purposes of this exercise, two full pallets of placebo vaccine were shipped by USDA
177 NVS to the IDALS designated storage site (MWI). In an actual outbreak, vaccine availability is
178 likely to be limited. Requests from the state for FMD vaccine must be approved by the U.S.
179 Chief Veterinary Officer. To support the request, the State Veterinarian must provide to the
180 USDA APHIS Veterinary Services FMD Incident Command Group the state's up-to-date FMD
181 Vaccination Plan and the Emergency FMD Vaccine Authorization and Request, found in the
182 USDA Foot-and-Mouth Disease Response Plan, The Red Book, Appendix E, Part I.

183 https://www.aphis.usda.gov/animal_health/emergency_management/downloads/fmd_responseplan.pdf

184 It is likely there will not be enough vaccine to meet all requests and the number of doses
185 allocated to each state will probably not correspond to full pallets of vaccine. The NVS would be
186 responsible for ensuring that pallets are broken down and the vaccine is repackaged into the
187 exact number of doses allocated to each state, all while maintaining the cold chain. In addition,
188 new cold chain monitors would need to be added to each shipment before delivery to the state.
189 Simultaneously, the vaccine need in each state may change as the outbreak develops. If the
190 approved number of doses has already been shipped to a state, it will be difficult to redistribute
191 vaccine to states with greater need. Using a vaccine distributor provides the USDA with the
192 ability to change the number of approved vaccine doses sent from the distributor to various states
193 on short notice to more effectively control the outbreak.

194

195 In this exercise, twenty full cases of vaccine (10 vials per case, 100cc/50 doses per vial) were
196 sent to each participating veterinary clinic. In an actual outbreak, it is likely that only the number
197 of doses approved for animals on each premises that the Category 2 accredited veterinarian is
198 approved to vaccinate will be shipped. Animal health distribution companies are much better
199 equipped than state officials to distribute partial boxes of vaccine vials.

200

201 **Proof of Concept**

202 As demonstrated in Phase Two of this exercise, there are many advantages to using independent
203 distributors to ensure proper vaccine handling and tracking in the event of a FAD. Rapid mass
204 distribution of resources is their area of expertise, and they complete these activities with a high
205 degree of accuracy and success on a daily basis. Advantages include:

- 206 • Ability to readily break down intact pallets of vaccine and quickly repackage the
207 authorized amount for shipment to authorized veterinarians;
- 208 • Ability to quickly redirect shipments to different locations or states depending on the
209 need determined by the USDA and State Animal Health Officials as the outbreak
210 progresses;
- 211 • Access to secure temperature-controlled storage;
- 212 • Trained personnel and software for receiving, shipping, and tracking;
- 213 • Already-established cold chain, chain of custody, and return policies and procedures; and
- 214 • Equipped to easily add extra supplies such as syringes and needles to shipments.

215 In summary, having arrangements in place with an independent distributor prior to a FAD
216 outbreak, will enable a more efficient and effective distribution of vaccine and more rapid
217 response to FMD.

218

219 **Lessons Learned**

220 Areas for improvement that were identified in Phase 2 through exercise play included better
221 communication with Authorized veterinarians on where in the packages the internal temperature
222 indicators were located and the importance of finding and reading the indicators. Step-by-step
223 instructions for veterinarians on unpackaging and documenting receipt of the vaccine should be
224 included in each box. An independent distributor could readily add this information to prevent
225 missing or ambiguous cold chain tracking data. Another concern was ensuring that information
226 on USDA CVB approved vaccine labels always accompanied the vaccine vials to the end user. It
227 is recommended that labels be affixed to each vial. If that is not possible because of the
228 emergency need to expedite shipment of vaccine, then an adequate supply of leaflets with the
229 label information should be available to accompany each vial of vaccine to the end user. This
230 repackaging could be accomplished by an independent distributor. In addition, policies and
231 procedures for deviations in cold chain maintenance should also be better defined.

232

233 **Conclusion**

234 This exercise successfully validated end-to-end vaccine logistics processes from FMD
235 confirmation in livestock in Iowa through vaccine distribution to individual veterinarians in five
236 states. Areas for improvement were identified and noted throughout the exercise. Furthermore,
237 the Iowa Department of Agriculture and Land Stewardship demonstrated multiple advantages to
238 partnering with an independent vaccine distributor to manage the placebo FMD vaccine cold
239 storage, repacking, and distribution process. The need for NVS and state officials to manage cold
240 storage, repackaging of the correct number of doses, and distribution, could be assumed by an

241 independent distributor rather than the NVS (shipping to states) and state officials (shipping to
242 approved veterinarians). It would also provide greater flexibility for just-in-time determination of
243 the number of doses to ship based on the current outbreak situation. Based on the outcomes of
244 this exercise, IDALS recommended that USDA or states consider working directly with one or
245 multiple independent vaccine distributors in the event of a foreign animal disease outbreak in the
246 U.S. when vaccine is utilized as a tool in response efforts. Independent distributors are readily
247 equipped to package, ship, and track mass distribution of animal health supplies while
248 maintaining cold chain and chain of custody. Utilizing these already established processes would
249 increase efficiency of the response, allow for regulatory officials and veterinarians to focus more
250 of their efforts on other vital response activities, and reduce potential error from the breakdown
251 and re-packaging of materials, ultimately ensuring the most effective use of valuable response
252 resources.

253

254 **Acknowledgements**

255 Funding for development of this paper was provided by IDALS to CFSPH. “FMD Vaccination
256 Distribution Concept; Fee for service agreement with CFSPH, 8/26/2022”

257 **The authors declare there are no conflicts of interest.**

258

259 **References**

- 260 1. Belsham, G. Towards improvements in foot-and-mouth disease vaccine performance.
261 Acta Veterinaria Scandinavica; 2020; 62(20). Accessed July 12, 2022
262 <https://actavetscand.biomedcentral.com/articles/10.1186/s13028-020-00519-1>

- 263 2. Spickler, A. Foot and Mouth Disease. Accessed November 15, 2021.
264 https://www.cfsph.iastate.edu/Factsheets/pdfs/foot_and_mouth_disease.pdf
- 265 3. U.S. Meat Export Federation, Export Statistics (2021), Beef Historical. Accessed June 4,
266 2022. <https://www.usmef.org/export-data/export-statistics>.
- 267 4. U.S. Meat Export Federation, Export Statistics (2021), Pork Historical, Accessed June 4,
268 2022. <https://www.usmef.org/export-data/export-statistics>
- 269 5. USDA Foreign Agriculture Service. Accessed June 4, 2022.
270 <https://fas.usda.gov/data/commodities/dairy-products>.
- 271 6. Personal communication, Amanda Chipman, Iowa Department of Agriculture and Land
272 Stewardship. October 20, 2021.
- 273 7. Draft Iowa Emergency Foot and Mouth Disease Vaccination Plan. Accessed July 12,
274 2022. <https://iowaagriculture.gov/animal-industry-bureau/foot-and-mouth-disease>

275

276

277 Figure Legend:

278 Figure 1. Photo of temperature indicator in range after shipment was received by authorized
279 personnel.

280